Business Context and Reporting Period
This Form 8-K Current Report was filed by GoodRx Holdings, Inc. on July 26, 2023. The filing discloses the formalization of a separation agreement with a former executive officer.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The financial data contained herein relates exclusively to the compensation and benefits associated with the executive departure.
Material Changes
The primary material change reported is the departure of Babak Azad, who served as Chief Marketing Officer and SVP, Marketing & Communications. His separation became effective on July 7, 2023, with a formal Separation Agreement & Release executed on July 26, 2023, and set to become effective on August 2, 2023.
Guidance, Outlook, and Unusual Items
The filing details the specific separation benefits provided to Mr. Azad, which constitute a one-time unusual item regarding executive compensation:
- Cash Payment: A lump sum of $205,000 (less taxes), payable within 14 days of the effective date.
- Equity Acceleration: Immediate vesting of unvested options for 50,000 shares and unvested restricted stock units (RSUs) for 20,402 shares.
- Exercise Extension: A six-month extension to exercise vested options for up to 275,000 shares (including accelerated options) at an exercise price of $5.94054 per share.
- Benefits: Reimbursement of COBRA premiums for nine months and six months of outplacement services.
In exchange, Mr. Azad agreed to a mutual release of claims and non-disparagement clauses. The filing contains no forward-looking guidance or management commentary regarding future business operations.
Investor Verification Checklist
- Verify the total potential equity value impact based on the current market price of Class A Common Stock versus the $5.94054 exercise price for the 275,000 shares subject to the extension.
- Confirm the exact timing of the $205,000 cash payout relative to the August 2, 2023 effective date.
- Review the full text of the Separation Agreement (Exhibit 10.1) for any additional restrictive covenants or conditions not summarized in the 8-K.
- Monitor subsequent filings for the appointment of a replacement Chief Marketing Officer.